KRAS and lung cancer: A recent in vivo study has shown that when WT-HRAS and WT-NRAS interact with mutated KRAS, specifically G12D in lung cancer, it effectively reduces KRAS dimerization, as well as decreases the amount of ERK downstream signaling.